Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors
- 1 September 1999
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 13 (13) , 1623-1627
- https://doi.org/10.1097/00002030-199909100-00004
Abstract
To determine the effect of the protease inhibitors ritonavir, nelfinavir and indinavir on the P-glycoprotein (P-gp)-mediated transport of saquinavir in Caco-2 cell monolayers. To study the modulation of P-gp function in human lymphocytes by saquinavir, ritonavir, nelfinavir and indinavir. We examined the effect of the protease inhibitors on P-gp function in human lymphocytes by using Rhodamine123 (Rh123; a fluorescent substrate of P-gp) by flow cytometry. Efflux of Rh123 correlates with P-gp function and inhibition of P-gp results in dye retention. Verapamil, a P-gp modulator and inhibitor of active transport at 4°C was used as a positive control. The transport of [14C]saquinavir (1μM) across Caco-2 cell monolayers was investigated, alone and in the presence of verapamil and ketoconazole (500μM) and the protease inhibitors at 100μM. Caco-2 cells are an in vitro model of the intestinal epithelium that is widely used for the study of P-gp function. The transport of saquinavir was determined in both the apical to basolateral (AP-BL) and basolateral to apical (BL-AP) directions. Saquinavir and ritonavir (10μM) markedly inhibited Rh123 efflux with an increase in fluorescence intensity similar to that obtained with verapamil. A small but statistically significant increase in fluorescence intensity was observed with nelfinavir; however indinavir did not modulate Rh123 efflux. In Caco-2 cells the apparent permeability coefficient for BL-AP efflux of saquinavir exceeded that for AP-BL efflux by a factor of 26: this is indicative of an active efflux pump. Known P-gp modulators caused a decrease in BL-AP efflux and an increase in AP-BL transport. The protease inhibitors displayed some P-gp modulation with ritonavir having the most potent effect. We have demonstrated that saquinavir is a substrate for P-gp and that ritonavir, nelfinavir and indinavir modulate P-gp function in both human lymphocytes and Caco-2 cells.Keywords
This publication has 12 references indexed in Scilit:
- HIV-1 Protease Inhibitors Are Substrates for theMDR1 Multidrug TransporterBiochemistry, 1998
- Active apical secretory efflux of the HIV protease inhibitors saquinavir and ritonavir in Caco-2 cell monolayers.Pharmaceutical Research, 1998
- Saquinavir Soft-Gel Capsule FormulationDrugs, 1998
- Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patientsAIDS, 1997
- Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavirBritish Journal of Clinical Pharmacology, 1997
- Saquinavir pharmacokinetics alone and in combination with ritonavir in HIV-infected patientsAIDS, 1997
- Abnormal Expression of a 170-Kilodalton P-Glycoprotein Encoded byMDR1Gene, a Metabolically Active Efflux Pump, in CD4+and CD8+T Cells from Patients with Human Immunodeficiency Virus Type 1 InfectionAIDS Research and Human Retroviruses, 1996
- Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapyMolecular Carcinogenesis, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.Proceedings of the National Academy of Sciences, 1987